Cargando…
Lost cost savings to the NHS in England due to the delayed entry of multiple generic low-dose transdermal buprenorphine: a case scenario analysis
OBJECTIVE: Originator pharmaceutical companies prolonging the patent of a medicine prevents rivals’ entry to the market and competition. As the entry of generic alternatives usually results in price reduction, any delay in their entry potentially deprives the National Health Service (NHS) of much-ne...
Autores principales: | Chapman, Stephen Robert, Aladul, Mohammed Ibrahim, Fitzpatrick, Raymond William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688687/ https://www.ncbi.nlm.nih.gov/pubmed/31375605 http://dx.doi.org/10.1136/bmjopen-2018-026817 |
Ejemplares similares
-
What drives the prescribing of growth hormone preparations in England? Prices versus patient preferences
por: Chapman, Stephen R, et al.
Publicado: (2017) -
NHS reforms in England: the implications for chemotherapy commissioning
por: Staines, Carolyn, et al.
Publicado: (2014) -
Complexity in the new NHS: longitudinal case studies of CCGs in England
por: Checkland, Katherine, et al.
Publicado: (2016) -
Variability and performance of NHS England’s ‘reason to reside’ criteria in predicting hospital discharge in acute hospitals in England: a retrospective, observational cohort study
por: Sapey, Elizabeth, et al.
Publicado: (2022) -
Opioids Aware: a general practice audit of high-dose opioid prescribing NHS England Midlands and East
por: Bastable, Ruth, et al.
Publicado: (2019)